1
|
Gutierrez M, Alonso A, Penha D, Ntouskou M, Gosney J, Radike M. Radiological-pathological correlation in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): imaging and histopathology. Clin Radiol 2024; 79:133-141. [PMID: 37945436 DOI: 10.1016/j.crad.2023.10.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 10/03/2023] [Accepted: 10/08/2023] [Indexed: 11/12/2023]
Abstract
AIM To review histologically confirmed diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) cases and carry out a detailed pathological-radiological correlation to see if computed tomography (CT) can be used to confidently identify DIPNECH. MATERIALS AND METHODS Twenty-three histologically confirmed DIPNECH patients in the shared database of two NHS Trusts were reviewed. CT images were reviewed by two independent radiologists, each of them with >10 years of experience in thoracic imaging. All histological specimens were reviewed by a single pathologist with >25 years of experience. The diagnosis of DIPNECH was made according to the current World Health Organization (WHO) definition included in the WHO 2015 classification of pulmonary tumours. The results on histology were compared to the presence of nodules and air trapping on CT. Demographic information and, when available, molecular imaging studies and pulmonary function tests were also considered. RESULTS There are prototypal clinical and radiological findings reflecting the presence of underlying histological DIPNECH: middle-aged women with multiple small and scattered nodules due to the clustering and proliferation of neuroendocrine cells. At least one larger, dominant, lung nodule reflecting a carcinoid tumour is very common and mosaic attenuation/air trapping is seen approximately in 50% of cases in inspiratory scans. Airflow obstruction is rarely associated with histological bronchial or peribronchial fibrosis, which suggests other mechanisms must be involved in its development. CONCLUSION CT can be used to predict pathological DIPNECH in the appropriate clinical setting. It is important to consider DIPNECH to avoid overdiagnosis of more sinister conditions such as lung cancer or metastases.
Collapse
Affiliation(s)
- M Gutierrez
- Department of Radiology, Liverpool Heart and Chest Hospital NHS Trust, Liverpool, UK.
| | - A Alonso
- Department of Radiology, Manchester University NHS Foundation Trust, Manchester, UK
| | - D Penha
- Department of Radiology, Liverpool Heart and Chest Hospital NHS Trust, Liverpool, UK
| | - M Ntouskou
- Department of Radiology, Liverpool Heart and Chest Hospital NHS Trust, Liverpool, UK
| | - J Gosney
- Cellular Pathology, Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, UK
| | - M Radike
- Department of Radiology, Liverpool Heart and Chest Hospital NHS Trust, Liverpool, UK
| |
Collapse
|
2
|
Ortiz Lizcano EI, Diaz I, Conry J, Garello N, Guevara E, Gutierrez M, Sridhar A, Bombas T, Malhotra J. Sexual and reproductive health and rights are basic human rights: The FLASOG Panama Declaration and FIGO Cartagena Declaration. Int J Gynaecol Obstet 2023. [PMID: 37144601 DOI: 10.1002/ijgo.14841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Affiliation(s)
| | - Ivonne Diaz
- FIGO, London, UK
- Universidad Militar Nueva Granada y Universidad Sanitas, Bogotá, Colombia
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Reyes-Rivera J, Vega ARG, Gutierrez M, Mendez-Rubio JJ, Ramírez-Muñiz DF, Shah AR, Allende-Carrera R. CLOPIDOGREL COULD BE THE NEW ASPIRIN FOR SECONDARY PREVENTION AFTER PCI. A SYSTEMATIC REVIEW. J Am Coll Cardiol 2023. [DOI: 10.1016/s0735-1097(23)02239-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
|
4
|
Castellano C, Loerinc L, Khan F, Cleary P, Gutierrez M, White M, McCool-Myers M, Camacho-Gonzalez A. Peer outreach program to improve condom education and use in young men who have sex with men living with HIV in Atlanta, GA. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00524-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
5
|
Borghaei H, Ciuleanu TE, Lee JS, Pluzanski A, Caro RB, Gutierrez M, Ohe Y, Nishio M, Goldman J, Ready N, Spigel DR, Ramalingam SS, Paz-Ares LG, Gainor JF, Ahmed S, Reck M, Maio M, O'Byrne KJ, Memaj A, Nathan F, Tran P, Hellmann MD, Brahmer JR. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. Ann Oncol 2023; 34:173-185. [PMID: 36414192 DOI: 10.1016/j.annonc.2022.11.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 09/22/2022] [Accepted: 11/11/2022] [Indexed: 11/21/2022] Open
Abstract
BACKGROUND First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC). We further characterized clinical benefit with this regimen in a large pooled patient population and assessed the effect of response on survival. PATIENTS AND METHODS Data were pooled from four studies of first-line nivolumab plus ipilimumab in advanced NSCLC (CheckMate 227 Part 1, 817 cohort A, 568 Part 1, and 012). Overall survival (OS), progression-free survival (PFS), objective response rate, duration of response, and safety were assessed. Landmark analyses of OS by response status at 6 months and by tumor burden reduction in responders to nivolumab plus ipilimumab were also assessed. RESULTS In the pooled population (N = 1332) with a minimum follow-up of 29.1-58.9 months, median OS was 18.6 months, with a 3-year OS rate of 35%; median PFS was 5.4 months (3-year PFS rate, 17%). Objective response rate was 36%; median duration of response was 23.7 months, with 38% of responders having an ongoing response at 3 years. In patients with tumor programmed death-ligand 1 (PD-L1) <1%, ≥1%, 1%-49%, or ≥50%, 3-year OS rates were 30%, 38%, 30%, and 48%. Three-year OS rates were 30% and 38% in patients with squamous or non-squamous histology. Efficacy outcomes in patients aged ≥75 years were similar to the overall pooled population (median OS, 20.1 months; 3-year OS rate, 34%). In the pooled population, responders to nivolumab plus ipilimumab at 6 months had longer post-landmark OS than those with stable or progressive disease; 3-year OS rates were 66%, 22%, and 14%, respectively. Greater depth of response was associated with prolonged survival; in patients with tumor burden reduction ≥80%, 50% to <80%, or 30% to <50%, 3-year OS rates were 85%, 72%, and 44%, respectively. No new safety signals were identified in the pooled population. CONCLUSION Long-term survival benefit and durable response with nivolumab plus ipilimumab in this large patient population further support this first-line treatment option for advanced NSCLC.
Collapse
Affiliation(s)
- H Borghaei
- Hematology and Oncology Department, Fox Chase Cancer Center, Philadelphia, USA.
| | - T-E Ciuleanu
- Department of Medical Oncology, Institutul Oncologic Prof Dr Ion Chiricuta, Cluj-Napoca; Department of Medical Oncology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania
| | - J-S Lee
- Department of Hematology/Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - A Pluzanski
- Department of Lung Cancer and Chest Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - R Bernabe Caro
- Medical Oncology Department, Hospital Universitario Virgen Del Rocio, Instituto de Biomedicina de Seville, Seville, Spain
| | - M Gutierrez
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, USA
| | - Y Ohe
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo
| | - M Nishio
- Department of Thoracic Medical Oncology Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - J Goldman
- David Geffen School of Medicine, UCLA, Los Angeles
| | - N Ready
- Department of Medicine, Duke University School of Medicine, Durham
| | - D R Spigel
- Thoracic Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology PLCC, Nashville
| | - S S Ramalingam
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, USA
| | - L G Paz-Ares
- Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
| | - J F Gainor
- Department of Medicine, Massachusetts General Hospital, Boston, USA
| | - S Ahmed
- Department of Medical Oncology, University Hospitals of Leicester, Leicester, UK
| | - M Reck
- Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, Lung Clinic, Grosshansdorf, Germany
| | - M Maio
- Center for Immuno-Oncology, University Hospital of Siena and University of Siena, Siena, Italy
| | - K J O'Byrne
- Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Australia
| | - A Memaj
- Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton
| | - F Nathan
- OneClinical, Bristol Myers Squibb, Princeton
| | - P Tran
- WW Medical Oncology Department, Bristol Myers Squibb, Princeton
| | - M D Hellmann
- Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York
| | - J R Brahmer
- Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore, USA
| |
Collapse
|
6
|
Simonelli M, Calvo E, Davar D, Richards D, Gutierrez M, Moreno Garcia V, Marron T, Rottey S, Orcurto A, Renouf D, Joerger M, Barriga Falcon S, Fan J, Gibson E, Chakraborty D, Arora V, Melero I. 200MO Anti–IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with advanced cancer: Update of initial phase I results. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
7
|
Endler M, Al‐Haidari T, Benedetto C, Chowdhury S, Christilaw J, El Kak F, Galimberti D, Gutierrez M, Ibrahim S, Kumari S, McNicholas C, Flores DM, Muganda J, Ramirez‐Negrin A, Senanayake H, Sohail R, Temmerman M, Gemzell Danielsson K, Gemzell-Danielsson K. Are sexual and reproductive health and rights taught in medical school? Results from a global survey. Int J Gynaecol Obstet 2022; 159:735-742. [PMID: 35809087 PMCID: PMC9804193 DOI: 10.1002/ijgo.14339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Revised: 06/14/2022] [Accepted: 07/07/2022] [Indexed: 01/05/2023]
Abstract
Our aim was to investigate the inclusion of sexual and reproductive health and rights (SRHR) topics in medical curricula and the perceived need for, feasibility of, and barriers to teaching SRHR. We distributed a survey with questions on SRHR content, and factors regulating SRHR content, to medical universities worldwide using chain referral. Associations between high SRHR content and independent variables were analyzed using unconditional linear regression or χ2 test. Text data were analyzed by thematic analysis. We collected data from 219 respondents, 143 universities and 54 countries. Clinical SRHR topics such as safe pregnancy and childbirth (95.7%) and contraceptive methods (97.2%) were more frequently reported as taught compared with complex SRHR topics such as sexual violence (63.8%), unsafe abortion (65.7%), and the vulnerability of LGBTQIA persons (23.2%). High SRHR content was associated with high-income level (P = 0.003) and low abortion restriction (P = 0.042) but varied within settings. Most respondents described teaching SRHR as essential to the health of society. Complexity was cited as a barrier, as were cultural taboos, lack of stakeholder recognition, and dependency on fees and ranking.
Collapse
Affiliation(s)
- Margit Endler
- Department of Women's and Children's HealthKarolinska Institutet and Karolinska University HospitalStockholmSweden
| | - Taghreed Al‐Haidari
- Scientific Affairs Unit, Al Kindy College of MedicineUniversity of BaghdadBaghdadIraq
| | - Chiara Benedetto
- Department of Gynecology and ObstetricsSant'Anna University HospitalTorinoItaly
| | | | - Jan Christilaw
- Faculty of MedicineUniversity of British ColumbiaVancouverCanada
| | - Faysal El Kak
- American University of BeirutBeirutLebanon,International Federation of Obstetricians and GynecologistsLondonUnited Kingdom
| | | | | | | | | | | | | | - John Muganda
- The Rwanda Society of Obstetricians and GynecologistsKigaliRwanda
| | | | | | - Rubina Sohail
- Services Institute of Medical Sciences/Services HospitalLahorePakistan
| | - Marleen Temmerman
- Aga Khan University, Nairobi, Kenya and Ghent UniversityGhentBelgium
| | - Kristina Gemzell Danielsson
- Department of Women's and Children's HealthKarolinska Institutet and Karolinska University HospitalStockholmSweden
| | - K Gemzell-Danielsson
- Department of Women´s and Children´s Health, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
8
|
Vilahur G, Radike M, Sutelman P, Ben-Aicha S, Gutierrez M, Casani L, Mendieta G, Hidalgo A, Fjellstrom O, Carlsson L, Badimon L. Administration of a human recombinant apyrase (AZD3366) limits myocardial tissue injury and improves cardiac function in a pig model of STEMI assessed by serial CMR. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Mitigating myocardial tissue injury (MTI) remains an unmet clinical need in the reperfusion era. Stimulating adenosine synthesis through the breakdown of adenosine triphosphate (ATP) by apyrase (CD39), an endothelial ADPase, has emerged as a potential new avenue in the reduction of MTI.
Purpose
In this study we examined whether the intravenous administration of a recombinant soluble form of human apyrase (AZD3366) prior to reperfusion limits MTI and improves cardiac function in a pig model of STEMI as assessed by serial cardiac magnetic resonance (CMR) imaging.
Methods
Pigs (n=16) were subjected to STEMI induction (1.5h closed-chest complete LAD coronary balloon occlusion). Immediately prior to reperfusion, pigs were randomized to intravenously receive one single dose of 3 mg/kg AZD3366 (n=8) or vehicle (n=8). Serial-CMR imaging was performed at baseline, 3 days, and 42 days post-MI for the assessment of structural and functional readouts at rest and during dobutamine stress. Light transmittance aggregometry (LTA; challenged by 5, 10 and 20 μM ADP) and ear bleeding time were monitored pre-MI, post-MI and at day 3.
Results
AZD3366 significantly reduced MTI by limiting (around 60%) oedema formation (21.3±6.7 vs. 12.3±6.7 g LV) and infarct size (14.3±6.1 vs. 8.4±3.4 g LV) and preventing microvascular obstruction (2.3±0.9 vs. 0.5±0.5 g LV) at 3 days post-MI, compared to vehicle-administered STEMI pigs (p<0.05). At a functional level, LVEDV and LVESV showed less deterioration in AZD3366 treated animal as compared to vehicle 3 days post-MI (p<0.05) and less numerical decrease of LVEF. Furthermore, AZD3366-treated animals showed no deterioration in LVEF upon dobutamine stress in contrast to vehicle-infused animals, (p<0.05). AZD3366 treatment nearly abolished LTA at all tested ADP doses early post-STEMI, an effect that remained up to 3 days post-infusion but did not affect ear bleeding time at any of the tested time points. No additional effects were seen at 42 days.
Conclusion
Infusion of one single dose of the soluble recombinant apyrase AZD3366 prior to reperfusion exerts cardioprotection by reducing oedema formation, microvascular obstruction and necrosis and improving cardiac performance at rest and after dobutamine stress during the acute post-MI period. Administration of AZD3366 as an adjunctive therapy to standard of care for STEMI patients undergoing primary PCI may reduce myocardial tissue injury.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): AstraZeneca, Gothenburg, Sweden
Collapse
Affiliation(s)
- G Vilahur
- Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, UAB, CIBERCV , Barcelona , Spain
| | - M Radike
- Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, UAB , Barcelona , Spain
| | - P Sutelman
- Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, UAB , Barcelona , Spain
| | - S Ben-Aicha
- Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, UAB , Barcelona , Spain
| | - M Gutierrez
- Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, UAB , Barcelona , Spain
| | - L Casani
- Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, UAB, CIBERCV , Barcelona , Spain
| | - G Mendieta
- National Centre for Cardiovascular Research (CNIC) , Madrid , Spain
| | - A Hidalgo
- Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Cardiology , Barcelona , Spain
| | - O Fjellstrom
- AstraZeneca, Research Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceutical R&D , Gothenburg , Sweden
| | - L Carlsson
- AstraZeneca, Bioscience Cardiovascular, Res. Early Develop., Cardiovascular, Renal Metabolism, BioPharmaceutical , Gothenburg , Sweden
| | - L Badimon
- Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, UAB, CIBERCV , Barcelona , Spain
| |
Collapse
|
9
|
Richardson G, Park J, Boyer M, Gutierrez M, Carbone D, Savvides P, Kaumaya P, Bekaii-Saab T, Phan T, Chong L, Cha S, Ede N, Nixon B, Withana N, Good A. P1.15-08 Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Hamilton E, Melero I, Lugowska I, Arance Fernandez A, Vila Martinez L, Powderly J, Gutierrez M, Serino T, Mehta N, Shapiro I, Whalen K, Michaelson J, Jones J, Janik J, Moreno Garcia V. 780TiP A phase I dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB Antibody) alone and in combination with pembrolizumab in patients with advanced malignancies. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
11
|
Reuss J, Wonser D, Smith K, Ahn J, Byers S, Creswell K, Kim C, Parikh K, Thompson J, Crawford J, Cohen E, Zeck J, Gutierrez M, Liu S. EP08.01-044 A Phase 2 Multi-Cohort Study of Tiragolumab, Atezolizumab and Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Cancer. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
12
|
Gutierrez M, Friedman C, Long G, Ascierto P, Melero I, Richards D, Bastos B, Moreno Garcia V, Uemura M, Conkling P, Corr B, Kim A, Zhu L, Hammell A, Perumal D, Chouzy A, Benavente F, Awosemo O, Hannah A, Le D. 740P Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
13
|
Gutierrez M, Bertolazzi C, Clavijo-Cornejo D, Cruz-Arenas E, Gomez-Quiroz LE, Salaffi F. POS1394 ULTRASOUND MAY DETECT SUBCLINICAL INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundInterstitial lung disease (ILD) is common in systemic sclerosis (SSc) patients and despite recent advances in the treatment represents still the major cause of death. It may be established within the first 4 years of SSc and frequently is subclinical [1].To evaluate the presence of ILD, there are different available tools in addition to the clinical evaluation including respiratory functional tests (RFT) and imaging methods, especially HRCT which remain the mainstay for the diagnosis of SSc-ILD.It has been recently proposed that pulmonary ultrasound (US) may have a potential role for the assessment of ILD in patients with SSc [2, 3]. Despite the growing body of evidence, there are no established data regarding its potential role in both detecting ILD in subclinical stages and on the follow-up of SSc patients.ObjectivesTo investigate the validity of US in detecting subclinical ILD in SSc and to determine its potential in the follow-up of these patients.Methods133 patients without respiratory symptoms and 133 healthy controls were included. Borg scale dyspnea index, Rodnan skin score (RSS) and pulmonary auscultation were performed. X-ray and respiratory function tests (RFT) were performed the same day. An expert rheumatologist blinded to clinical assessment performed the US. To determine the concurrent validity high-resolution CT (HRCT) scans was performed. HRCT findings were scored according to Warrick score whereas US findings were classified according the previously proposed scale. An inter-observer reliability was performed. A follow-up including US, RFT and Borg scale was done every 3 months for 12 months.ResultsA total of 54 of 133 SSc patients (40.6%) showed US signs of ILD in contrast to healthy controls (4.8%) (p=0.0001). The clinical and laboratory variables associated with ILD were anti-centromere antibodies (p=0.005) and RSS (p=0.004). A positive correlation was demonstrated between the US and HRCT findings (p=0.001). Sensitivity and specificity of US in detecting ILD was 91.2% and 88.6% respectively. A good inter-observer reliability was also observed (k = 0.72).In the follow-up, a total of 30 patients (22.6%) that demonstrated US signs of ILD at baseline showed US worsening. Nine patients (30%) developed symptoms of ILD.ConclusionUS is valid to detect subclinical ILD-SSc. Our results showed a high prevalence of this complication. Despite encouraging data, it seems still controversial its role in monitoring the ILD progression in SSc.References[1]Salaffi F, Carotti M, Baldelli S, et al. Subclinical interstitial lung involvement in rheumatic diseases. Correlation of high resolution computerized tomography and functional and cytologic findings. Radiol Med 1999;97:33-41.[2]Tardella M, Gutierrez M, Salaffi F, et al. Ultrasound in the assessment of pulmonary fibrosis in connective tissue disorders: correlation with high-resolution computed tomography. J Rheumatol 2012; 39:1641-47.[3]Gargani L, Doveri M, D’Errico L, et al. Ultrasound lung comets in systemic sclerosis: a chest sonography hallmark of pulmonary interstitial fibrosis. Rheumatology 2009;48:1382-87.Disclosure of InterestsNone declared
Collapse
|
14
|
Gutierrez M, Ruta S, Clavijo-Cornejo D, Fuentes-Moreno G, Reyes-Long S, Bertolazzi C. POS1393 ULTRASOUND AS A POTENTIAL TOOL TO DETECT INTERSTITIAL LUNG DISEASE IN DAILY CLINICAL SETTING OF PATIENTS WITH RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundInterstitial lung disease (ILD) is the most common and relevant pulmonary complication, that contributes significantly to increased morbidity and mortality in rheumatoid arthritis (RA). Thus, increased awareness of this complication is a real challenge in the clinical setting; in particular, an accurate strategy to detect RA-ILD is crucial to assure the survival and quality of life of RA patients.In the last years, the pulmonary ultrasound (US) has been proposed to assess ILD in rheumatic diseases [1, 2]. Preliminary results have demonstrated a positive correlation between their findings and those of HRCT and diffusion capacity of carbon monoxide (DLCO).Although these results are exciting, the value and potential application of US in detect ILD in daily clinical setting of patients with RA remain to be clearly delineated.ObjectivesTo investigate the potential role of US in the detection of ILD in a real-life cohort of patients with RA.MethodsPatients with diagnosis of RA were consecutively enrolled. All patients underwent pulmonary examination, laboratory data, DLCO measure, chest HRCT and radiographs, and US examination. A healthy group was included as control group.US was performed according the 14-intercostal space scanning protocol using the following semiquantitative scale [0 = normal (≤5 B-lines); 1 = slight (≥6 and ≤15 B-lines); 2 = moderate, (≤16 and ≥30 B-lines); 3 = severe (≥30 B-lines)].ResultsA total of 74 RA patients and 74 healthy controls were included. Thirty of 74 patients (40.5%) showed US signs of ILD with respect to the healthy controls (3 subjects, 4.1%) (p=0.0001); whereas HRCT showed ILD in 27 (36.4%) of 74 patients.Among the 30 patients that showed US findings of ILD, 17 (56.6%) were asymptomatic from respiratory view-point. The sensitivity and specificity of US were 92% and 89% respectively.A positive correlation between US and HRCT findings were found (p= < 0.0001) whereas no correlation was found with chest radiographs and DLCO findings (p = 0.2971 and 0.7856 respectively). Positive association between US findings and DAS28-ESR, RF and anti-CCP (p=0.0076, 0.0044, 0.0074 respectively) was found.Feasibility, represented by the mean time spent to perform the pulmonary US assessment was 7.8 minutes (± SD 1.2, range 6 to 10 minutes).ConclusionOur results support the potential of US in detect accurately ILD in a real-life cohort of patients with RA and provide a rationale to consider it as a friendly screening tool to be implemented in early phases of the disease.References[1]Gutierrez M, Salaffi F, Carotti M, et al. Utility of a simplified ultrasound assessment to assess interstitial pulmonary fibrosis in connective tissue disorders-preliminary results. Arthritis Res Ther 2011Aug 18;13-R134.[2]Moazedi-Fuerst FC, Kielhauser S, Brickmann K, et al. Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus. Clin Exp Rheumatol 2015;33:S87-91.AcknowledgementsTo the Pan-American League of Rheumatology Associations (PANLAR).Disclosure of InterestsNone declared
Collapse
|
15
|
Shitara K, Golan T, Mileham K, Voskoboynik M, Rha S, Gutierrez M, Perets R, Taylor S, Chen D, Keenan T, Rajasagi M, Healy J, Shoji H. PD-3 Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
16
|
Sirotti S, Becce F, Sconfienza LM, Terslev L, Zanetti A, Naredo E, Zufferey P, Gutierrez M, Adinolfi A, Serban T, Maccarter D, Mouterde G, Scanu A, Möller I, Scirè CA, Sarzi-Puttini P, Novo-Rivas U, Abhishek A, Choi H, Dalbeth N, Tedeschi S, Iagnocco A, Pineda C, Keen H, D’agostino MA, Filippou G. POS0276 TRADITION VS INNOVATION! CONVENTIONAL RADIOGRAPHY AND ULTRASOUND IN THE DIAGNOSIS OF CPPD: INSTRUCTIONS FOR USE. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundConventional radiography (CR) is widely used as the first-line investigation for calcium pyrophosphate deposition (CPPD) disease, given its widespread use and the low cost. Next to it a series of advanced imaging techniques have been evaluated for accuracy and reliability. Among them, ultrasound (US) has been thoroughly tested and demonstrated to be accurate and reliable for CPPD diagnosis. However, even if there are data on the diagnostic accuracy of US and CR alone, it is not clear if performing both diagnostic tests and in which sequential order provides an added value for the diagnosis of CPPD.ObjectivesThe aim of this study was to assess which diagnostic test performs better for the diagnosis of CPPD and if a combination of the two exams provides an additional value.MethodsThis is an ancillary study of the criterion validity of US in CPPD study1. Consecutive patients with knee osteoarthritis requiring total joint replacement were enrolled in 8 centres. Participants underwent US and CR of the affected knee prior to surgery. US was performed by experienced sonographers following the same scanning protocol described in the main study, while CR were performed in weight bearing AP and lateral views and were read by 2 experienced radiologists that reached a consensus on the presence/absence of CPPD. The evaluation of CPPD at the level of menisci and hyaline cartilage (HC) was based on the OMERACT definitions for US and on the new definitions developed by the ACR/EULAR CPPD classification criteria working group for CR [paper under submission]. Patients were classified as having CPPD considering histological examination as reference standard. Diagnostic indexes were calculated for US and CR alone and combined. Poisson models with robust estimation were used to estimate the best sequence of these diagnostic methods for a more accurate diagnosis of CPPD.Results51 pts were enrolled (63% F, mean age 74y ± 8). Diagnostic indexes of US and CR alone and combined are indicated in Table 1. Compared to histology, US demonstrated to be a sensitive tool for identification of CPPD at the knee, with a good sensitivity in all sites and in the overall evaluation. Instead, CR was less sensitive, but it was a highly specific exam for CPPD identification. Combining US and CR led to a higher sensitivity compared with CR alone, but a lower specificity compared to both CR and US alone, and it offered no additional increase in diagnostic accuracy. The Figure 1 shows the results of the appropriate sequence of use of US and CR in patients with suspected CPPD: in case of a positive CR at any of the 3 sites (menisci and HC) no additional exam is necessary, and the same in case of a positive US in at least two sites; however in case of a negative CR, US could help in a statistically significant way to identify CPPD patients, and further in case of a positive US in a single site CR can offer additional information.Table 1.diagnostic indexes of US, CR and US + CR in the identification of CPPD. MM: medial meniscus, LM: lateral meniscus, HC: hyaline cartilage, SN: sensitivity, SP: specificity, PPV: positive predictive value, NPV: negative predictive value, ACC: accuracy.USSNSPPPVNPVACCMM0.880.810.820.880.84LM0.880.730.760.860.80HC0.780.860.820.830.82Overall0.920.640.730.890.78CRMM0.32110.610.67LM0.400.960.910.630.69HC0.480.930.850.680.73Overall0.540.920.880.660.73US + CRMM0.880.810.820.880.84LM0.920.690.740.900.80HC0.870.820.800.890.84Overall0.920.560.670.880.75Figure 1.evaluation of sequence of US and CRConclusionUS confirmed a high diagnostic accuracy in identifying patients affected by CPPD at knee level, while CR demonstrated a high specificity but a low sensitivity. Performing both diagnostic tests could make sense in case of a negative CR or in case of an inconclusive US (only one positive site). To our knowledge, this is the first study that investigates the role of the combination of the two exams in CPPD. Further studies in a large number of patients and in different joints would be helpful to address this point.References[1]Filippou G. et al, Ann Rheum Dis, 2020Disclosure of InterestsNone declared
Collapse
|
17
|
Corro Verde U, Navarrete Solano P, Fabregat Borras R, Raba Diez J, Cañón Garcia V, Vazquez Rodriguez J, Albendea Roch J, Gutierrez M, Astudillo Olalla R, Rivero Perez A, Arrojo Alvarez E, Pinto Guevera F, Pacheco Baldor M, Diaz De Cerio I, Prada Gomez P. PO-1130 Stereotactic Radiosurgery for trigeminal neuralgia using Exactrac Dynamic. First experience. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03094-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Parikh K, Ma L, Treuner K, Wong J, Schnabel C, Gutierrez M. P59.05 Integration of Molecular Cancer Classification and NGS to Identify Metastatic Cancer Patients Eligible For Lung Cancer Directed Therapy. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Sirotti S, Gutierrez M, Pineda C, Clavijo-Cornejo D, Serban T, Dumitru A, Scanu A, Adinolfi A, Scirè CA, Sarzi Puttini P, D'Agostino MA, Keen HI, Terslev L, Iagnocco A, Filippou G. Accuracy of synovial fluid analysis compared to histology for the identification of calcium pyrophosphate crystals: an ancillary study of the OMERACT US Working Group - CPPD subgroup. Reumatismo 2021; 73:106-110. [PMID: 34342211 DOI: 10.4081/reumatismo.2021.1403] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Accepted: 04/15/2021] [Indexed: 11/23/2022] Open
Abstract
The aim of this study was to evaluate the accuracy of synovial fluid analysis in the identification of calcium pyrophosphate dihydrate crystals compared to microscopic analysis of joint tissues as the reference standard. This is an ancillary study of an international, multicentre cross-sectional study performed by the calcium pyrophosphate deposition disease (CPPD) subgroup of the OMERACT Ultrasound working group. Consecutive patients with knee osteoarthritis (OA) waiting for total knee replacement surgery were enrolled in the study from 2 participating centres in Mexico and Romania. During the surgical procedures, synovial fluid, menisci and hyaline cartilage were collected and analysed within 48 hours from surgery under transmitted light microscopy and compensated polarised light microscopy for the presence/absence of calcium pyrophosphate crystals. All slides were analysed by expert examiners on site, blinded to other findings. A dichotomic score (absence/ presence) was used for scoring both synovial fluid and tissues. Microscopic analysis of knee tissues was considered the gold standard. Sensitivity, specificity, accuracy, positive and negative predictive values of synovial fluid analysis in the identification of calcium pyrophosphate crystals were calculated. 15 patients (53% female, mean age 68 yo ± 8.4) with OA of grade 3 or 4 according to Kellgren-Lawrence scoring were enrolled. 12 patients (80%) were positive for calcium pyrophosphate crystals at the synovial fluid analysis and 14 (93%) at the tissue microscopic analysis. The overall diagnostic accuracy of synovial fluid analysis compared with histology for CPPD was 87%, with a sensitivity of 86% and a specificity of 100%, the positive predictive value was 100% and the negative predictive value was 33%. In conclusion synovial fluid analysis proved to be an accurate test for the identification of calcium pyrophosphate dihydrate crystals in patients with advanced OA.
Collapse
Affiliation(s)
- S Sirotti
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Italy; Rheumatology Department, Luigi Sacco University Hospital, Milan.
| | - M Gutierrez
- Division of Musculoskeletal and Rheumatic Diseases, Instituto Nacional de Rehabilitacion, Mexico City.
| | - C Pineda
- Division of Musculoskeletal and Rheumatic Diseases, Instituto Nacional de Rehabilitacion, Mexico City.
| | - D Clavijo-Cornejo
- Division of Musculoskeletal and Rheumatic Diseases, Instituto Nacional de Rehabilitacion, Mexico City.
| | - T Serban
- Rheumatology Department, Ospedale La Colletta, ASL3 Genovese, Genoa.
| | - A Dumitru
- Department of Pathology, "Carol Davila University of Medicine and Pharmacy", Bucharest.
| | - A Scanu
- Department of Medicine-DIMED, Rheumatology Unit, University of Padova.
| | - A Adinolfi
- Rheumatology Department, ASST Grande Ospedale Metropolitano Niguarda, Milano.
| | - C A Scirè
- Società Italiana di Reumatologia, Epidemiology Research Unit, Milan.
| | - P Sarzi Puttini
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Italy; Rheumatology Department, Luigi Sacco University Hospital, Milan.
| | - M-A D'Agostino
- Rheumatology Department, Università Cattolica del Sacro Cuore, Policlinico Universitario Agostino Gemelli IRCSS, Roma.
| | - H I Keen
- School of Medicine, The University of Western Australia, Murdoch, Perth.
| | - L Terslev
- Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University, Copenhagen.
| | - A Iagnocco
- Academic Rheumatology Centre, Department of Clinical and Biological Sciences, Università degli Studi di Torino.
| | - G Filippou
- Rheumatology Department, Luigi Sacco University Hospital, Milan.
| |
Collapse
|
20
|
Cañón V, Anchuelo J, Diaz de Cerio I, Cardenal J, Ferri M, Garcia Blanco A, Corro U, Navarrete P, Galdós P, Rivero A, Albendea J, Astudillo R, Gutierrez M, Alonso J, Alonso L, Vidal H, Velasco S, Fabregat R, Ruiz S, Garnacho M, Aviles A, Pacheco M, Prada P. PO-1489 Radiotherapy in benign pathology: treatment of lymphorrheas. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07940-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Adinolfi A, Sirotti S, Gutierrez M, Pineda C, Clavijo Cornejo D, Serban T, Dumitru A, Scanu A, D’agostino MA, Keen H, Terslev L, Sarzi-Puttini P, Scirè CA, Iagnocco A, Filippou G. AB0629 ACCURACY OF SYNOVIAL FLUID ANALYSIS FOR THE IDENTIFICATION OF CALCIUM PYROPHOSPHATE CRYSTALS: AN ANCILLARY STUDY OF OMERACT CRITERION VALIDITY STUDY FOR ULTRASOUND IN CPPD. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.601] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Synovial fluid analysis (SFA) via compensated polarized light microscopy is still considered the gold standard for the identification and diagnosis of Calcium Pyrophosphate Deposition disease (CPPD)-related arthropathies[1], but very few studies have been published about its diagnostic accuracy.Objectives:The aim of this study was to evaluate the accuracy of SFA in the identification of calcium pyrophosphate dihydrate (CPP) crystals compared to microscopic analysis of joint tissues as the reference standard.Methods:This is an ancillary study of an international, multicentre cross-sectional study performed by the CPPD subgroup of the OMERACT Ultrasound working group[2]. Consecutive patients with knee osteoarthritis (OA) waiting for total knee replacement surgery were enrolled in the study from 2 participating centres, Mexico and Romania. During surgical procedures synovial fluid (SF), menisci and hyaline cartilage were collected and analysed within 48 hours after surgery under transmitted light microscopy and compensated polarised light microscopy for the presence/absence of CPP crystals. All slides were analysed by expert examiners on site, blinded to other findings. A dichotomic score (absence/presence) was used for scoring both SF and tissues. Microscopic analysis of knee tissues was considered the gold standard. Sensitivity, specificity, accuracy, positive and negative predictive values (PPV and NPV) of SFA in the identification of CPP crystals were calculated.Results:15 patients (53% female, mean age 68yo ± 8.4) with OA of grade 3 or 4 according to Kellgren-Lawrence scoring were enrolled. 12 patients (80%) were positive for CPP crystals at SFA and 14 (93%) at tissues microscopic analysis. Among 12 SFA positive patients, all were positive for CPP crystals in either medial or lateral meniscus, and 11 were positive in both; 10 patients were positive at the hyaline cartilage, and all 10 were also positive for at least one meniscus. Regarding the 3 SFA negative patients, only one had no crystals in the examined tissues, while the other 2 patients had CPP crystals in both menisci and hyaline cartilage. The overall diagnostic accuracy of SFA compared to histology analysis for CPPD was 87%, with a sensitivity of 86% and a specificity of 100%, the PPV was 100% and the NPV was 33% (Table 1).Table 1.sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy of synovial fluid analysis compared to the reference standard. CI: Confidential Interval. SF: synovial fluid, in parentheses: numerators and denominators for all percentages provided.SensitivitySpecificityPPVNPVAccuracySF analysis86% (12/14)100% (1/1)100% (12/12)33% (1/3)87% (13/15)(0.65-0.99) CI 95%(0.0-0.25) CI 95%(0.65-0.99) CI 95%(0.0-0.25) CI 95%Conclusion:SFA demonstrated to be an accurate test for the identification of CPP crystals in patients with advanced OA. However, is not always feasible and carries some risks for the patient. Considering the availability of validated imaging techniques for the detection of CPPD, such as US, SFA could be used in those patients where imaging and clinical data are not definitely confirmatory of the disease.References:[1]W. Zhang et al., ‘European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis’, Ann Rheum Dis, vol. 70, no. 4, pp. 563–570, Apr. 2011, doi: 10.1136/ard.2010.139105.[2]G. Filippou et al., ‘Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study’, Ann Rheum Dis, p. annrheumdis-2020-217998, Sep. 2020, doi: 10.1136/annrheumdis-2020-217998.Disclosure of Interests:None declared.
Collapse
|
22
|
Sirotti S, Becce F, Sconfienza LM, Pineda C, Gutierrez M, Serban T, Maccarter D, Adinolfi A, Naredo E, Scanu A, Scirè CA, Möller I, Sarzi-Puttini P, Abhishek A, Choi H, Dalbeth N, Tedeschi S, D’agostino MA, Keen H, Terslev L, Iagnocco A, Filippou G. POS1132 DIAGNOSTIC ACCURACY OF CONVENTIONAL RADIOGRAPHY OF THE KNEE FOR CALCIUM PYROPHOSPHATE DEPOSITION DISEASE: AN ANCILLARY STUDY OF THE OMERACT ULTRASOUND – CPPD GROUP. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Conventional Radiography (CR) has been widely used in the assessment of knee chondrocalcinosis (CC) and is still considered one of the most important diagnostic methods for the diagnosis. However, there are very few studies that examine the diagnostic accuracy of CR compared to histology of the knee tissues.Objectives:To assess the diagnostic accuracy of CR of the knee in Calcium Pyrophosphate Deposition Disease (CPPD) by using the recently created definitions for CPPD in CR of the ACR/EULAR taskforce for the new classification criteria for CPPD.Methods:This is an ancillary study of the Criterion Validity of Ultrasound in CPPD study [1]. Consecutive patients with osteoarthritis (OA) awaiting total knee replacement were enrolled in 4 centres from Romania, Italy, USA and Mexico. All patients underwent CR of the knees taken maximum 6 months before surgery, in posterior-anterior weight baring and lateral projections. DICOM files of the radiographs were anonymised and read independently by two musculoskeletal radiologists with experience in microcrystalline arthropathies. For each patient, a dichotomic score was used (absence/presence of CC) at the level of the menisci and tibiofemoral hyaline cartilage by each reader. The definitions of the ACR/EULAR taskforce for identification of CPPD in CR were used in this study [paper in preparation]. According to these definitions CPPD in CR appears as “linear or punctate opacities in the region of fibro- or hyaline articular cartilage/synovial membrane or joint capsule/within tendons or entheses that are distinct from denser, nummular radio-opaque deposits due to basic calcium phosphate deposition”. In case of disagreement a consensus decision was taken by both radiologists after discussion of the case. Menisci and the hyaline cartilage were analysed using compensated polarized light microscopy as described previously [1], patients were considered positive for CPPD if at least one of their tissue specimens revealed the presence of calcium pyrophosphate crystals. All examiners were blind to each other’s findings.Results:We enrolled 33 patients with OA (61% female, mean age 69yo). The accuracy values of CR in the various sites of the knee are indicated in Table 1. CR demonstrated to be a specific exam for identification of CPPD at the knee, but sensitivity remains low in all sites and in the overall evaluation. Identification of CPPD appears challenging and this could be due to the advanced grade of OA in our cohort of patients. Advanced degeneration, dislocation of the menisci and thinning of the hyaline cartilage in these patients is frequent and the eventual presence of calcific deposits in one of these structures could overlap with other anatomical structures making the exact localisation difficult. According to the results of the predictive values, the presence of typical deposition on CR allows a definite confirmation of the diagnosis, but a negative radiography does not exclude CPPD as testified by the low negative predictive value.Table 1.Sensitivity, specificity, PPV, NPV, accuracy and AUC of CR for identification of CPPD by using the new ACR/EULAR taskforce definitions.Medial meniscusLateral meniscusHyaline cartilageOverallSensitivity22%33%31%42%Specificity100%100%85%90%Positive predictive value100%100%67%80%Negative predictive value56%60%55%61%Accuracy61%68%58%66%AUC0.60.70.60.7Conclusion:CR has been extensively used for the diagnosis of OA and CPPD and has been tested previously for diagnostic accuracy. The results of our study confirm that the presence of typical CPPD calcifications, as defined by the ACR/EULAR task force, are highly specific but have low sensitivity for disease identification when using CR. Absence of CPPD on CR does not exclude the diagnosis.References:[1]Filippou G, et al. Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study. Ann Rheum Dis 2020. doi:10.1136/annrheumdis-2020-217998Disclosure of Interests:None declared.
Collapse
|
23
|
Sirotti S, Becce F, Sconfienza LM, Pineda C, Gutierrez M, Serban T, Maccarter D, Adinolfi A, Naredo E, Scanu A, Möller I, Sarzi-Puttini P, Abhishek A, Choi H, Dalbeth N, Tedeschi S, D’agostino MA, Keen H, Terslev L, Iagnocco A, Filippou G. POS1133 RELIABILITY OF CONVENTIONAL RADIOGRAPHY OF THE KNEE FOR THE ASSESSMENT OF CHONDROCALCINOSIS: AN ANCILLARY STUDY OF THE OMERACT ULTRASOUND – CPPD GROUP. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Conventional Radiography (CR) has been widely used in the assessment of knee chondrocalcinosis (CC) and is still considered one of the most important diagnostic methods for the diagnosis. However, there are no studies on the reliability of CR for CC.Objectives:To assess the reliability of CR of the knee in the assessment of chondrocalcinosis (CC).Methods:This is an ancillary study of the Criterion Validity of Ultrasound in Calcium Pyrophosphate Deposition Disease (CPPD) study [1]. Consecutive patients with knee osteoarthritis (OA) that were planned for total knee replacement surgery were enrolled in 4 centres from Romania, Italy, USA and Mexico. All patients underwent CR of the knees taken maximum 6 months before surgery, in posterior-anterior weight baring and lateral projections. DICOM files of the radiographs were retrieved, anonymised and read independently by two musculoskeletal radiologists with experience in microcrystalline arthropathies. Each reader performed a second evaluation 3 weeks after the first one to calculate the inter- and intra-reader agreement. For each patient a dichotomic score was assigned (absence/presence of CC) at the level of the medial and lateral menisci, tibiofemoral hyaline cartilage, quadriceps and patella tendons, synovial membrane/joint capsule. The definitions of the ACR/EULAR taskforce for identification of CPPD in conventional radiography were used in this study [paper in preparation]. According to these definitions CPPD in CR appears as “linear or punctate opacities in the region of fibro- or hyaline articular cartilage/synovial membrane or joint capsule/within tendons or entheses that are distinct from denser, nummular radio-opaque deposits due to basic calcium phosphate deposition”. Cohen’s kappa was used to calculate the agreement between the two readers.Results:We enrolled 33 patients with knee OA (60.6% female, mean age 69yo ± 8). The kappa values of the inter-reader and intra-reader agreement in the various sites of the knee are indicated in Table 1. Inter-reader agreement was substantial at the level of both menisci but only moderate or fair at the other sites of assessment. This had a negative impact on the overall evaluation of the knee joint that proved to be unreliable (k of 0.16 – none to slight agreement) if all anatomical structures are included for assessment, and moderately reliable (kappa 0.41) when both menisci and hyaline cartilage are considered. On the other hand, intra-reader kappa values were substantial or higher in all sites (except for synovial membrane/joint capsule for one reader). The striking difference of the intra-reader compared to the inter-reader kappa values, highlight a different interpretation and application of the definitions used for most of the sites with the exception of the menisci.Table 1.kappa values for intra- and inter-reader agreement. Values from 0.01–0.20 are considered as none to slight agreement, 0.21–0.40 as fair, 0.41– 0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1.00 as almost perfect agreement.Medial meniscusLateral meniscusHyaline cartilageQuadriceps tendonPatellar tendonCapsule/ synoviaMenisci + cartilageEntire jointInter-reader0.670.710.340.47NA0.370.400.17Intra-reader 1st assessor0.670.900.840.65NA(insufficient number of categories)0.530.710.76Intra-reader 2nd assessor10.801110.910.860.94Conclusion:CR has been extensively used for diagnosis of OA and CPPD. The results of our study raise some concerns on the reliability of CR in identification of CPPD. Assessment of calcium crystals at the menisci level should be used for identification of CC as other sites of the knee seem to present low reliability.References:[1]Filippou G et al. Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study. Ann Rheum Dis 2020. doi:10.1136/annrheumdis-2020-217998Disclosure of Interests:None declared.
Collapse
|
24
|
Tedeschi S, Pascart T, Latourte A, Godsave C, Kundaki B, Naden R, Taylor W, Dalbeth N, Neogi T, Perez-Ruiz F, Rosenthal A, Becce F, Pascual E, Andrés M, Bardin T, Doherty M, Ea HK, Filippou G, Fitzgerald J, Gutierrez M, Iagnocco A, Jansen T, Kohler M, Lioté F, Matza M, Mccarthy G, Ramonda R, Reginato A, Richette P, Singh J, Sivera F, So A, Stamp L, Yinh J, Yokose C, Terkeltaub R, Choi H, Abhishek A. POS1124 IDENTIFYING POTENTIAL CLASSIFICATION CRITERIA FOR CALCIUM PYROPHOSPHATE DEPOSITION DISEASE (CPPD): RESULTS FROM THE INITIAL PHASES. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Classification criteria for calcium pyrophosphate deposition disease (CPPD) will facilitate clinical research on this common crystalline arthritis. ACR/EULAR are jointly sponsoring development of CPPD classification criteria using a multi-phase process.Objectives:To report preliminary results from the first two phases of a four-phase process for developing CPPD classification criteria.Methods:CPPD classification criteria development is overseen by a 12-member Steering Committee. Item generation (Phase I) included a scoping literature review of five literature databases and contributions from a 35-member Combined Expert Committee and two Patient Research Partners. Item reduction and refinement (Phase II) involved a Combined Expert Committee meeting, discussions among Clinical, Imaging, and Laboratory Advisory Groups, and an item rating exercise to assess the influence of individual items toward classification. The Steering Committee reviewed the modal rating score for each item (range -3 [strongly pushes away from CPPD] to +3 [strongly pushes toward CPPD]) to determine items to retain for future phases of criteria development.Results:Item generation yielded 420 items (312 from the literature, 108 from experts/patients). The Advisory Groups eliminated items they agreed were unlikely to distinguish between CPPD and other forms of arthritis, yielding 127 items for the item rating exercise. Fifty-six items, most of which had a modal rating of +/- 2 or 3, were retained for future phases (see Table 1). As numerous imaging items were rated +3, the Steering Committee recommended focusing on imaging of the knee, wrist, and one additional affected joint for calcification suggestive of CPP crystal deposition.Conclusion:The ACR/EULAR CPPD classification criteria working group has adopted both data- and expert-driven approaches, leading to 56 candidate items broadly categorized as clinical, imaging, and laboratory features. Remaining steps for criteria development include domain establishment, item weighting through a multi-criteria decision analysis exercise, threshold score determination, and criteria validation.Table 1.Categories of items retained for future phases of classification criteria developmentAge in decade at symptom onsetAcute inflammatory arthritis (e.g. knee, wrist, 1st MTP joint*)Recurrence and pattern of joint involvement (e.g. 1 self-limited episode, >1 self-limited episode)Physical findings (e.g. palpable subcutaneous tophus*, psoriasis*)Co-morbidities and family history (e.g. Gitelman disease, hemochromatosis, familial CPPD)Osteoarthritis location and features (e.g. 2nd or 3rd MCP joint, wrist)Synovial fluid findings (e.g. CPP crystals present, CPP crystals absent on 1 occasion* or 2 occasions*, monosodium urate crystals present*)Laboratory findings (e.g. hypomagnesemia, hyperparathyroidism, rheumatoid factor*, anti-CCP*)Plain radiograph: calcification in regions of fibro- or hyaline cartilage+Plain radiograph: calcification of the synovial membrane/capsule/tendon+Conventional CT: calcification in regions of fibro- or hyaline cartilage+Conventional CT: calcification of the synovial membrane/capsule/tendon+Ultrasound: CPP crystal deposition in fibro- or hyaline cartilage+Ultrasound: CPP crystal deposition in synovial membrane/capsule/tendons+Dual-energy CT: CPP crystal deposition in fibro- or hyaline cartilage+Dual-energy CT: CPP crystal deposition in synovial membrane/capsule/tendon+*Potential negative predictor +Assessed in the knee, wrist, and/or 1 additional affected jointDisclosure of Interests:Sara Tedeschi Consultant of: NGM Biopharmaceuticals, Tristan Pascart: None declared, Augustin Latourte Consultant of: Novartis, Cattleya Godsave: None declared, Burak Kundaki: None declared, Raymond Naden: None declared, William Taylor: None declared, Nicola Dalbeth Speakers bureau: Abbvie and Janssen, Consultant of: AstraZeneca, Dyve, Selecta, Horizon, Arthrosi, and Cello Health, Tuhina Neogi: None declared, Fernando Perez-Ruiz: None declared, Ann Rosenthal: None declared, Fabio Becce Consultant of: Horizon Therapeutics, Grant/research support from: Siemens Healthineers, Eliseo Pascual: None declared, Mariano Andrés: None declared, Thomas Bardin: None declared, Michael Doherty: None declared, Hang Korng Ea: None declared, Georgios Filippou: None declared, John FitzGerald: None declared, Marwin Gutierrez: None declared, Annamaria Iagnocco: None declared, Tim Jansen Speakers bureau: Abbvie, Amgen, BMS, Grunenthal, Olatec, Sanofi Genzyme, Consultant of: Abbvie, Amgen, BMS, Grunenthal, Olatec, Sanofi Genzyme, Minna Kohler Speakers bureau: Lilly, Consultant of: Novartis, Frederic Lioté: None declared, Mark Matza: None declared, Geraldine McCarthy Consultant of: PK Med, Roberta Ramonda: None declared, Anthony Reginato: None declared, Pascal Richette: None declared, Jasvinder Singh Speakers bureau: Simply Speaking, Consultant of: Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio health, Medscape, WebMD, Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, Practice Point communications, Francisca Sivera: None declared, Alexander So: None declared, Lisa Stamp: None declared, Janeth Yinh: None declared, Chio Yokose: None declared, Robert Terkeltaub Consultant of: Sobi, Horizon Therapeutics, Astra-Zeneca, Selecta, Grant/research support from: Astra-Zeneca, Hyon Choi: None declared, Abhishek Abhishek Consultant of: NGM Biopharmaceuticals.
Collapse
|
25
|
Cho B, Perets R, Rasco D, Ahn MJ, Spigel D, Yoh K, Kim DW, Gutierrez M, Lee D, Nagrial A, Satouchi M, Kotasek D, Maurice-Dror C, Niu J, Rajasagi M, Siddiqi S, Li X(N, Cyrus J, Altura R, Bar J. TS01.02 Novel Anti–CTLA-4 Antibody Quavonlimab Plus Pembrolizumab as First-Line Therapy for NSCLC: Extended Follow-up From a Phase 1 Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Endler M, Al-Haidari T, Benedetto C, Chowdhury S, Christilaw J, El Kak F, Galimberti D, Garcia-Moreno C, Gutierrez M, Ibrahim S, Kumari S, McNicholas C, Mostajo Flores D, Muganda J, Ramirez-Negrin A, Senanayake H, Sohail R, Temmerman M, Gemzell-Danielsson K. How the coronavirus disease 2019 pandemic is impacting sexual and reproductive health and rights and response: Results from a global survey of providers, researchers, and policy-makers. Acta Obstet Gynecol Scand 2020; 100:571-578. [PMID: 33179265 PMCID: PMC8247356 DOI: 10.1111/aogs.14043] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Revised: 10/26/2020] [Accepted: 11/05/2020] [Indexed: 02/01/2023]
Abstract
INTRODUCTION We aimed to give a global overview of trends in access to sexual and reproductive health and rights (SRHR) during the coronavirus disease 2019 (COVID-19) pandemic and what is being done to mitigate its impact. MATERIAL AND METHODS We performed a descriptive analysis and content analysis based on an online survey among clinicians, researchers, and organizations. Our data were extracted from multiple-choice questions on access to SRHR services and risk of SRHR violations, and written responses to open-ended questions on threats to access and required response. RESULTS The survey was answered by 51 people representing 29 countries. Eighty-six percent reported that access to contraceptive services was less or much less because of COVID-19, corresponding figures for surgical and medical abortion were 62% and 46%. The increased risk of gender-based and sexual violence was assessed as moderate or severe by 79%. Among countries with mildly restrictive abortion policies, 69% had implemented changes to facilitate access to abortion during the pandemic, compared with none among countries with severe restrictions (P < .001), 87.5% compared with 46% had implemented changes to facilitate access to contraception (P = .023). The content analysis showed that (a) prioritizations in health service delivery at the expense of SRHR, (b) lack of political will, (c) the detrimental effect of lockdown, and (d) the suspension of sexual education, were threats to SRHR access (theme 1). Requirements to mitigate these threats (theme 2) were (a) political will and support of universal access to SRH services, (b) the sensitization of providers, (c) free public transport, and (d) physical protective equipment. A contrasting third theme was the state of exception of the COVID-19 pandemic as a window of opportunity to push forward women's health and rights. CONCLUSIONS Many countries have seen decreased access to and increased violations of SRHR during the COVID-19 pandemic. Countries with severe restrictions on abortion seem less likely to have implemented changes to SRHR delivery to mitigate this impact. Political will to support the advancement of SRHR is often lacking, which is fundamental to ensuring both continued access and, in a minority of cases, the solidification of gains made to SRHR during the pandemic.
Collapse
Affiliation(s)
- Margit Endler
- Department of Women and Children's Health, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden
| | - Taghreed Al-Haidari
- Scientific Affairs Unit, Al Kindy College of Medicine, University of Baghdad, Baghdad, Iraq
| | - Chiara Benedetto
- Department of Gynecology and Obstetrics, Sant´Anna University Hospital, Torino, Italy
| | - Sameena Chowdhury
- Obstetrical and Gynecological Society of Bangladesh, Dhaka, Bangladesh
| | - Jan Christilaw
- Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Faysal El Kak
- American University of Beirut, Beirut, Lebanon, and International Federation of Obstetricians and Gynecologists, London, UK
| | | | | | | | | | | | | | - Desirée Mostajo Flores
- The Bolivian Society of Obstetricians and Gynecologists, Santa Cruz de la Sierra La Paz, Bolivia
| | - John Muganda
- The Rwanda Society of Obstetricians and Gynecologists, Kigali, Rwanda
| | | | | | - Rubina Sohail
- Services Institute of Medical Sciences/Services Hospital, Lahore, Pakistan
| | - Marleen Temmerman
- Aga Khan University, Nairobi, Kenya and Ghent University, Ghent, Belgium
| | - Kristina Gemzell-Danielsson
- Department of Women and Children's Health, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
27
|
Perets R, Bar J, Rasco DW, Ahn MJ, Yoh K, Kim DW, Nagrial A, Satouchi M, Lee DH, Spigel DR, Kotasek D, Gutierrez M, Niu J, Siddiqi S, Li X, Cyrus J, Chackerian A, Chain A, Altura RA, Cho BC. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol 2020; 32:395-403. [PMID: 33276076 DOI: 10.1016/j.annonc.2020.11.020] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 11/13/2020] [Accepted: 11/20/2020] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Quavonlimab (MK-1308), a novel anti-CTLA-4 antibody, in combination with pembrolizumab was investigated in a phase I study. PATIENTS AND METHODS Dose-escalation (DE) phase: patients with advanced/metastatic solid tumors received an initial flat dose of quavonlimab as monotherapy [25 mg (cohort 1), 75 mg (cohort 2), or 200 mg (cohort 3)] followed by four treatments of the same quavonlimab dose plus pembrolizumab every 3 weeks (Q3W). Dose-confirmation phase (DC): patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) received first-line quavonlimab [25 mg Q3W (arm A), 25 mg Q6W (arm B), 75 mg Q6W (arm C), or 75 mg Q3W (arm E)] plus pembrolizumab. Primary objectives were safety and tolerability and establishment of the recommended phase II dose (RP2D) of quavonlimab when used with pembrolizumab. Objective response rate (ORR) was a secondary endpoint. Efficacy based on PD-L1 expression, tumor mutational burden (TMB), and changes in circulating CD4+/CD8+ cells were exploratory endpoints. RESULTS Thirty-nine patients were enrolled in DE [n = 14 (cohort 1); n = 17 (cohort 2); n = 8 (cohort 3)] and 134 in DC [n = 40 (arm A); n = 40 (arm B); n = 40 (arm C); n = 14 (arm E)]. Maximum-tolerated dose was not reached. Grade 3-5 treatment-related adverse events (AEs; graded according to NCI CTCAE v4.03) occurred in 0%, 23.5%, and 75.0% of patients in DE cohorts 1, 2, and 3, respectively, and 35.0%, 30.0%, 35.0%, and 57.1% of patients in DC arms A, B, C, and E, respectively. Efficacy was observed at all dose levels/schedules in patients with NSCLC. ORRs were 40.0% [95% confidence interval (CI), 24.9-56.7; arm A], 37.5% (95% CI, 22.7-54.2; arm B), 27.5% (95% CI, 14.6-43.9; arm C), and 35.7% (95% CI, 12.8-64.9; arm E). PD-L1 expression and total number of circulating CD4+ cells correlated with ORR. CONCLUSIONS Quavonlimab 25 mg Q6W plus pembrolizumab demonstrated similar efficacy and a better safety profile among all quavonlimab doses/schedules evaluated; this regimen was the chosen RP2D.
Collapse
Affiliation(s)
- R Perets
- Department of Oncology, Rambam Medical Center, Technion-Israel Institute of Technology, Haifa, Israel
| | - J Bar
- Cancer Center, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | | | - M-J Ahn
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, South Korea
| | - K Yoh
- Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - D-W Kim
- Department of Hemato Oncology, Medical Oncology Center, and Personalized Cancer Medicine Center, Seoul National University Hospital, Seoul, South Korea
| | - A Nagrial
- Department of Cancer and Hematology, Blacktown Hospital and University of Sydney, Sydney, Australia
| | - M Satouchi
- Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan
| | - D H Lee
- Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
| | - D R Spigel
- Department of Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, USA
| | - D Kotasek
- Department of Medical Oncology, Adelaide Cancer Centre and University of Adelaide, Kurralta Park, Australia
| | - M Gutierrez
- Department of Hematology, Hematology Oncology, and Medical Oncology, Hackensack University Medical Center, Hackensack, USA
| | - J Niu
- Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, USA
| | - S Siddiqi
- MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA
| | - X Li
- MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA
| | - J Cyrus
- MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA
| | - A Chackerian
- Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, USA
| | - A Chain
- MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA
| | - R A Altura
- MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA
| | - B C Cho
- Division of Medical Oncology, Yonsei Cancer Center, Seoul, South Korea.
| |
Collapse
|
28
|
Vilahur G, Arzanauskaite M, Sutelman P, Ben-Aicha S, Gutierrez M, Casani L, Fjellstrom O, Carlsson L, Hidalgo A, Badimon L. Administration of a soluble ADPase, AZD3366, on top of ticagrelor confers additional cardioprotective benefits to that of ticagrelor alone. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Preclinical and pilot human studies suggest platelet-independent cardioprotective effects of ticagrelor most likely due to its ability to block cellular uptake of adenosine. Adenosine is a potent endogenous protective molecule, concentrations of which locally rise as a response to ischemia because of the breakdown of extracellular ATP by an endothelial ADPase (apyrase, CD39) to AMP that is subsequently converted to adenosine by CD73.
Purpose
In the present study we used cardiac magnetic resonance (CMR) imaging in a pig model of myocardial infarction (MI) to examine whether administration of a recombinant soluble form of ADPase, AZD3366 (APT102), confers additional benefits to that of ticagrelor alone in terms of reduced infarct size and improved heart function.
Methods
Pigs (n=20) were administered an oral loading dose of ticagrelor (180mg) and 2h later subjected to MI induction (1.5h closed-chest LAD coronary balloon occlusion). Prior to reperfusion, pigs were randomized to intravenously receive 1) vehicle (n=5); 2) 1mg/kg AZD3366 (n=5); or 3) 3mg/kg AZD3366 (n=5). After reperfusion all pigs were administered ticagrelor (90mg/bid) for 42 days. A non-treated control-MI group (n=5) was run for comparative purposes. Serial-CMR imaging was performed at baseline and 3 and 42 days post-MI for global and regional structural and functional assessments. Light transmittance aggregometry (LTA; challenged by 5, 10 and 20μM ADP) and ear bleeding time were monitored throughout the study.
Results
Ticagrelor significantly reduced edema formation (29.8±1.9 vs. 13.1±0.9%LV) and limited infarct size (17.7±1.5 vs. 8.2±1.2%LV) at 3 days post-MI as compared to control-MI pigs (p<0.05), an effect that persisted up to 42 days. Infusion of 1mg/kg AZD3366 showed a clear signal towards further prevention of myocardial damage that reached significance at doses of 3mg/kg (additional reduction of 35% and 52% in edema and infarct size, respectively, as compared to pigs treated with ticagrelor alone; p<0.05). Left ventricular ejection fraction was higher in all ticagrelor-treated pigs at 3 and 42 days post-MI vs. control (p<0.05). Yet, regional analysis of the jeopardized myocardium revealed that pigs administered 3mg/kg AZD3366 on top of ticagrelor presented minimal dysfunctional segmental contraction as compared to the mild hypokinetic and akinetic disturbances observed in ticagrelor-alone and control-MI pigs (χ2 p<0.05 vs. all). Ticagrelor inhibited ADP-induced platelet aggregation by 30% and addition of AZD3366 acutely abolished (90% inhibition) LTA at all tested ADP doses, an effect remaining significant up to 3 days post-infusion. Ear bleeding time was not affected by AZD3366.
Conclusion
Infusion of a soluble recombinant ADPase (AZD3366) on top of ticagrelor leads to a greater cardioprotection as compared to ticagrelor alone. Co-administration of both drugs in AMI patients undergoing revascularization deserves to be investigated.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Ministerio de Ciencia, Innovaciόn y Universidades / Instituto de Salud Carlos III
Collapse
Affiliation(s)
- G Vilahur
- Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, CIBERCV, Barcelona, Spain
| | - M Arzanauskaite
- Cardiovascular Program ICCC, IR-Hospital Sant Pau, Barcelona, Spain
| | - P Sutelman
- Cardiovascular Program ICCC, IR-Hospital Sant Pau, Barcelona, Spain
| | - S Ben-Aicha
- Cardiovascular Program ICCC, IR-Hospital Sant Pau, Barcelona, Spain
| | - M Gutierrez
- Cardiovascular Program ICCC, IR-Hospital Sant Pau, Barcelona, Spain
| | - L Casani
- IR-Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - O Fjellstrom
- AstraZeneca, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Gothenburg, Sweden
| | - L Carlsson
- AstraZeneca, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Gothenburg, Sweden
| | - A Hidalgo
- Hospital de la Santa Creu i Sant Pau, Cardiology, Barcelona, Spain
| | - L Badimon
- Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, UAB, CIBERCV, Barcelona, Spain
| |
Collapse
|
29
|
Martinez-Herrera E, Gutierrez M, Molina JC. ZIGZAG-KM for a comprehension and integrated action as answer to the Emergency Climate Declaration. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa166.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The headline goal for SDG13 focus specially on strengthening resilience, adaptive capacity to climate-related hazards and natural disasters as well as integrating climate change measures into national policies, strategies and planning. In Colombia, the increase in rainfall and temperature jeopardize the well-being of the population. The Transdisciplinary Seminar on Environmental Health and Climate Change drives the strengthening of multisectoral research on impacts and vulnerability in the territory, promotes the construction of collective adaptation strategies that mitigate the health effects of recent emergency climate declaration.
Objective
ZIGZAG Knowledge Management (ZIGZAG-KM) generate common points from a collective construction on the Climate Change Adaptation Plan from the Environmental Health Component guided by participants. The steps of this methodology lead the stakeholders to develop practical constructions with freedom of adaptation and change, capacity for a new learning culture and an opportunity for collaboration in a team that identifies and balances their interests from a community approach, local resilience and citizen science. After 18 months we concrete a consensus Report on the determination of the contextual vulnerability analysis as a technical outcomes, nowadays, the scientific results are running on and will be included in a Report of collaborative learning about citizen scientists oriented for implement strategies of the adaptation plan with a community approach for Antioquia and the strengthening citizen participation actions to impulse collectively resilience to climate change. This Seminar was structured about multidisciplinary theoretical rules and transdisciplinary practical considerations, which will contribute in the social understanding of adaptation strategies.
Conclusions
In spite of the efforts, the culture of knowledge transformation continues to be limited due to interests that may arise among the participants.
Key messages
ZIGZAG-KM learning guided by experts, decision makers and defenders of health and the environment. Transdisciplinary orientation in thematic dialogues and actions is useful health adaptation on Climate Change and Emergency Climate Declaration.
Collapse
Affiliation(s)
- E Martinez-Herrera
- National School of Public Health, Universidad de Antioquia, Medellín, Colombia
- Health inequalities Research Group, Universtat Pompeu Fabra, Barcelona, Spain
- Public Policy Center, JHU-UPF, Barcelona, Spain
| | - M Gutierrez
- National School of Public Health, Universidad de Antioquia, Medellín, Colombia
| | - J C Molina
- National School of Public Health, Universidad de Antioquia, Medellín, Colombia
| |
Collapse
|
30
|
Guigay J, Lee KW, Patel M, Daste A, Wong D, Goel S, Gordon M, Gutierrez M, Balmanoukian A, Le Tourneau C, Mita A, Vansteene D, Keilholz U, Schöffski P, Grote H, Zhou D, Bajars M, Penel N. 920P Avelumab (anti-PD-L1) in patients with platinum-refractory/ineligible recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Results from a phase Ib cohort. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
31
|
Filippou G, Scanu A, Adinolfi A, Toscano C, Gambera D, Largo R, Naredo E, Calvo E, Herrero-Beaumont G, Zufferey P, Madelaine-Bonjour C, Maccarter D, Makman S, Weber Z, Figus F, Möller I, Gutierrez M, Pineda C, Clavijo Cornejo D, García H, Ilizaliturri V, Mendoza Torres J, Pichardo R, Rodriguez Delgado LC, Filippucci E, Cipolletta E, Serban T, Cirstoiu C, Vreju FA, Grecu D, Mouterde G, Govoni M, Punzi L, Damjanov N, Terslev L, Scirè CA, Iagnocco A. OP0317 ACCURACY OF THE OMERACT DEFINITIONS FOR IDENTIFICATION OF CALCIUM PYROPHOSPHATE CRYSTALS WITH ULTRASOUND: FINAL RESULTS OF THE OMERACT US IN CPPD SUB-TASK FORCE STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:The OMERACT Ultrasound (US) in calcium pyrophosphate deposition disease (CPPD) sub-task force has been working on the use of US in CPPD since 2014 first creating definitions for CPPD identification and then assessing the reliability[1].Objectives:Objective of this study is to assess the diagnostic accuracy (truth) of US in CPPD.Methods:Consecutive patients waiting to undergo knee replacement surgery due to osteoarthritis were enrolled in 12 centres from 6 countries. Each patient underwent US examination of the knee, focusing on the menisci and the hyaline cartilage, the day prior to surgery, scoring each site for presence/absence of CPP as defined previously[1]. After surgery, the menisci and the condyles were retrieved and examined microscopically. Six samples were collected, both from the surface and from the internal part of menisci and cartilage trying to cover a large part of it. All slides were observed under transmitted light microscopy and by compensated polarised microscopy. A dichotomous score was given for the presence/absence of CPP. US and microscopic analysis were performed by different operators, blind to each other’s findings. Sensitivity and specificity of US were calculated using microscopic findings as the gold standard.Results:101 patients have been enrolled in the study. 33 patients have been excluded due to loss of anatomical pieces at surgery. The mean age of the remaining 68 pts was 71yo (±8), 44 women, 34 were affected by CPPD according to microscopy. Overall and per site diagnostic US accuracy results are presented in table 1Diagnostic accuracySensitivitySpecificityPositive Predictive valueNegative Predictive valueGlobal0.750.910.590.690.87Medial meniscus0.820.870.770.770.87Lateral meniscus0.750.830.680.680.83Medial cartilage0.860.790.920.880.85Lateral cartilage0.820.710.880.770.84Medial side (combined cartilage and meniscus)0.820.880.760.790.87Lateral side (combined cartilage and meniscus)0.780.880.690.730.86Conclusion:Our results demonstrate that US is an accurate exam for identification of CPPD. The best combination of sensitivity and specificity is achieved by examining the medial aspect of the knee.References:[1]Filippou G, Scirè CA, Adinolfi A,et al.Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasound: reliability of the OMERACT definitions in an extended set of joints—an international multiobserver study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force.Ann Rheum Dis2018;:annrheumdis-2017-212542. doi:10.1136/annrheumdis-2017-212542Disclosure of Interests:Georgios Filippou: None declared, Anna Scanu: None declared, Antonella Adinolfi: None declared, Carmela Toscano: None declared, Dario Gambera: None declared, Raquel Largo: None declared, Esperanza Naredo: None declared, Emilio Calvo: None declared, Gabriel Herrero-Beaumont: None declared, Pascal Zufferey: None declared, Christel Madelaine-Bonjour: None declared, Daryl MacCarter: None declared, Stanley Makman: None declared, Zachary Weber: None declared, Fabiana Figus: None declared, Ingrid Möller: None declared, Marwin Gutierrez: None declared, Carlos Pineda: None declared, Denise Clavijo Cornejo: None declared, Héctor García: None declared, Victor Ilizaliturri: None declared, Jaime Mendoza Torres: None declared, Raul Pichardo: None declared, Luis Carlos Rodriguez Delgado: None declared, Emilio Filippucci Speakers bureau: Dr. Filippucci reports personal fees from AbbVie, personal fees from Bristol-Myers Squibb, personal fees from Celgene, personal fees from Roche, personal fees from Union Chimique Belge Pharma, personal fees from Pfizer, outside the submitted work., Edoardo Cipolletta: None declared, Teodora Serban: None declared, Catalin Cirstoiu: None declared, Florentin Ananu Vreju: None declared, Dun Grecu: None declared, Gael Mouterde: None declared, Marcello Govoni: None declared, Leonardo Punzi: None declared, Nemanja Damjanov Grant/research support from: from AbbVie, Pfizer, and Roche, Consultant of: AbbVie, Gedeon Richter, Merck, Novartis, Pfizer, and Roche, Speakers bureau: AbbVie, Gedeon Richter, Merck, Novartis, Pfizer, and Roche, Lene Terslev Speakers bureau: LT declares speakers fees from Roche, MSD, BMS, Pfizer, AbbVie, Novartis, and Janssen., Carlo Alberto Scirè: None declared, Annamaria Iagnocco Grant/research support from: Abbvie, MSD and Alfasigma, Consultant of: AbbVie, Abiogen, Alfasigma, Biogen, BMS, Celgene, Eli-Lilly, Janssen, MSD, Novartis, Sanofi and Sanofi Genzyme, Speakers bureau: AbbVie, Alfasigma, BMS, Eli-Lilly, Janssen, MSD, Novartis, Sanofi
Collapse
|
32
|
Torres Esteche V, Torres I, Aleman A, Soto J, Fernandez L, Romero L, Liencres A, Garcia C, Gutierrez M. CANNABIS CONSUMPTION RELATED TO CHRONIC AND ACUTE RESPIRATORY SYMPTOMS. Chest 2020. [DOI: 10.1016/j.chest.2020.05.504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
33
|
Torres I, Gutierrez M, Torres V, Aleman A, Soto J, Romero L, Fernandez L, Liencres A. LUNG FUNCTION IN CANNABIS SMOKERS. Chest 2020. [DOI: 10.1016/j.chest.2020.05.505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
34
|
Endler M, Al Haidari T, Chowdhury S, Christilaw J, El Kak F, Galimberti D, Gutierrez M, Ramirez-Negrin A, Senanayake H, Sohail R, Temmerman M, Danielsson KG. Sexual and reproductive health and rights of refugee and migrant women: gynecologists' and obstetricians' responsibilities. Int J Gynaecol Obstet 2020; 149:113-119. [PMID: 32012258 DOI: 10.1002/ijgo.13111] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Ensuring universal access to sexual and reproductive healthcare services is Target 3.7 of the United Nations Sustainable Development Goals (SDG). Refugee and migrant women and children are at particular risk of being forgotten in the global momentum to achieve this target. In this article we discuss the violations of sexual and reproductive health and rights (SRHR) of particular relevance to the refugee and migrant reality. We give context-specific examples of denial of health services to vulnerable groups; lack of dignity as a barrier to care; the vulnerability of adolescents; child marriage; weaponized rape; gender-based violence; and sexual trafficking. We discuss rights frameworks and models that are being used in response to these situations, as well as what remains to be done. Specifically, we call for obstetricians and gynecologists to act as individual providers and through their FIGO member societies to protect women's health and rights in these exposed settings.
Collapse
Affiliation(s)
- Margit Endler
- Department of Women's and Children's Health, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.,Women's Health Reserch Unit, University of Cape Town, Cape Town, South Africa
| | | | | | - Jan Christilaw
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
| | - Faysal El Kak
- Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon
| | - Diana Galimberti
- Department of Obstetrics and Pediatrics, Hospital General de Agudos Dr Teodoro Alvarez, Buenos Aires, Argentina
| | | | - Atziri Ramirez-Negrin
- National Institute of Perinatology, Hospital General Dr Manuel Gea Gonzáles, Mexico City, Mexico
| | - Hemantha Senanayake
- Department of Obstetrics and Gynecology, University of Colombo, Colombo, Sri Lanka
| | - Rubina Sohail
- Services Institute of Medical Sciences, Service Hospital Lahore, Lahore, Pakistan
| | - Marleen Temmerman
- Aga Khan University, Nairobi, Kenya.,Ghent University, Ghent, Belgium
| | - Kristina Gemzell Danielsson
- Department of Women's and Children's Health, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden
| | | |
Collapse
|
35
|
Menon S, Ellis C, Poudel S, Johnson J, Szabo A, George B, Kevin Kelly W, Grant S, McPherson J, Cristofanilli M, Hoimes C, Gutierrez M, Doudement J, Chan L, Singal G, Alexander B, Miller V, Sohal D. B08 Impact of Concurrent STK11 Loss and c-MYC Amplification in Metastatic Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2020. [DOI: 10.1016/j.jtho.2019.12.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
36
|
Cabezas J, Rojas D, Melo-Baez B, Gutierrez M, Castro F, Rodriguez-Alvarez L. 52 Blocking of embryonic development by nanoparticles derived from endometrial and oviductal cells isolated with an Amicon filter system. Reprod Fertil Dev 2020. [DOI: 10.1071/rdv32n2ab52] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
The success of development of invitro embryo production needs to mimic culture conditions in the maternal environment. Recently, it has been seen that extracellular vesicles (EVs) secreted by oviducal or endometrial cells may improve development and quality of embryos produced invitro. Extracellular vesicles are a mechanism of cellular communication; they carry molecules that are delivered into the target cells changing gene expression and function. Due to the size range and characteristics of EVs, they require specific methods for purification and characterisation. However, the possible contamination with other nanoparticles and their effect on embryo development have not been considered. Based on that, the goal of this work was to evaluate the effect on invitro bovine embryo development, of the addition to culture medium EVs secreted by oviducal and endometrial cells and isolated by centrifugation and concentrates with Amicon filters. For this purpose, cells were isolated from bovine oviduct and endometrium collected in local abattoir and primary cultures of epithelial and stromal cells were derived. The primary cultures from both sources were exposed or not to progesterone (P4; 15ngmL−1) for 4 days and then cultured for 24h in EV depleted media. The supernatant was harvested and EVs were isolated by serial centrifugations and subsequently concentrated by a 100 kDa Amicon filter system. The isolated EVs were characterised by transmission electron microscopy, nanoparticle tracking analysis, and flow cytometry. Oocytes were obtained from ovaries collected in the abattoir. The cumulus-oocyte complexes were matured invitro for 22h and subsequently fertilised for 18h. Presumptive zygotes were invitro cultured in synthetic oviducal fluid with EVs (1000ngmL−1 of total proteins) or not according to experimental group (1: EVs− (control); 2: EVs−OP4+; 3: EVs−OP4−; 4: EVs−EP4+ and 4: EVs−EP4−). Embryos were cultured for 7 days in 5% CO2, 5% O2, and 90% N2 (25 embryos/well in 4-well plates). At Day 7, embryo development was evaluated considering the blastocyst yield. Transmission electron microscopy showed typical structures and morphology of EVs and they were positive for CD9, CD63, and CD81 markers, and negative for CD40. According to nanoparticle tracking analysis, the mean size of EVs was 160±62nm and concentration of 3.29×1011 particlesmL−1 for oviducal and endometrial cells, respectively. A significant reduction of blastocyst rate was observed when embryos were cultured with cell-derived EVs; control: 152/44 (28.9%) vs. treatments with EVs; OP4+: 74/3 (4.1%), OP4−:76/2 (2.6%), EP4+: 74/6 (8.1%), and EP4−: 73/2 (2.7%) (P ≤ 0.01). Our results indicate that the use of nanoparticles, including EVs, isolated from cells of oviduct or endometrium, has a blocking effect on embryonic development and compromises the performance of blastocysts on Day 7 when used at concentrations of 1000ngmL−1 total protein, independent of the use or not of P4 and the source. These data provide insights regarding the use and protocols of acquiring exosomes for embryo supplementation.
This research was supported by FONDECYT, Chile-1170310.
Collapse
|
37
|
Cornu JY, Randriamamonjy S, Gutierrez M, Rocco K, Gaudin P, Ouerdane L, Lebeau T. Copper phytoavailability in vineyard topsoils as affected by pyoverdine supply. Chemosphere 2019; 236:124347. [PMID: 31310975 DOI: 10.1016/j.chemosphere.2019.124347] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 06/21/2019] [Accepted: 07/09/2019] [Indexed: 06/10/2023]
Abstract
Pyoverdine (Pvd) is a bacterial siderophore produced by some Pseudomonads species that can bind copper in addition to iron in soil. Pvd is expected to alter the dynamics and the ecotoxicity of Cu in vineyard soils. This study investigated the extent to which the mobility and the phytoavailability of Cu varied among vineyard soils with different pH and how they were affected by a supply of Pvd. Pvd was supplied (or not) to ten vineyard topsoils with pH ranging from 5.9 to 8.6 before metal was extracted with 0.005 M CaCl2. Cu mobility was assessed through its total concentration and Cu phytoavailability through its free ionic concentration measured in the CaCl2 extract. Cu mobility varied by a factor of six and Cu phytoavailability by a factor of 5000 among the soil samples. In the CaCl2 extract, the concentration of Cu2+ was not correlated with the concentration of total Cu but was correlated with pH. This revealed that Cu phytoavailability depends to a great extent on Cu complexation in soil pore water, the latter being highly sensitive to pH. Adding Pvd enhanced the mobility of Cu in the soils including in carbonate soils. The Pvd-mobilization factor for Cu varied from 1.4 to 8 among soils, linked to the availability of Fe and Al in the solid phase and to Pvd partitioning between the solid and the liquid phase. Adding Pvd reduced the concentration of Cu2+ in CaCl2 extract, which challenges the idea of using Pvd-producing bacteria to promote Cu phytoextraction.
Collapse
Affiliation(s)
- J Y Cornu
- ISPA, Bordeaux Sciences Agro, INRA, 33140, Villenave d'Ornon, France.
| | - S Randriamamonjy
- ISPA, Bordeaux Sciences Agro, INRA, 33140, Villenave d'Ornon, France; LPG, UMR 6112 CNRS-Université de Nantes, BP 92208, 44322, Nantes, Cedex 3, France
| | - M Gutierrez
- ISPA, Bordeaux Sciences Agro, INRA, 33140, Villenave d'Ornon, France
| | - K Rocco
- ISPA, Bordeaux Sciences Agro, INRA, 33140, Villenave d'Ornon, France
| | - P Gaudin
- LPG, UMR 6112 CNRS-Université de Nantes, BP 92208, 44322, Nantes, Cedex 3, France
| | - L Ouerdane
- IPREM, UMR 5254 CNRS-Université de Pau et des Pays de l'Adour, Hélioparc, 64053, Pau, France
| | - T Lebeau
- LPG, UMR 6112 CNRS-Université de Nantes, BP 92208, 44322, Nantes, Cedex 3, France
| |
Collapse
|
38
|
Cho B, Yoh K, Bar J, Nagrial A, Spigel D, Gutierrez M, Kim DW, Kotasek D, Rasco D, Niu J, Satouchi M, Ahn MJ, Lee D, Maurice-Dror C, Siddiqi S, Li X, Cyrus J, Altura R, Perets R. Results From a Phase I Study of MK-1308 (ANTI–CTLA-4) Plus Pembrolizumab in Previously Treated Advanced Small Cell Lung Cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz451.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Mozola MA, Peng X, Wendorf M, Alles S, Artiga L, Buchholz T, Camacho A, Charveron N, Clayborn J, Decker C, Deibel C, Donohue T, Draughon A, Ewings J, Feldworth M, Gane P, Goodwin J, Gunter T, Gutierrez M, Hovland R, Jechorek R, Jones W, Keskinen L, Lamproe B, Larson E, Manwarren H, Merkling A, Osing C, Pangloli P, Remes A, Richter E, Rogers A, Rose B, Ryser E, Secraw S, Slupik M, Wessinger A, Westmoreland R, Yan Z, Zahoor T, Zhang L. Evaluation of the GeneQuence® DNA Hybridization Method in Conjunction with 24-Hour Enrichment Protocols for Detection of Salmonella spp. in Select Foods: Collaborative Study. J AOAC Int 2019. [DOI: 10.1093/jaoac/90.3.738] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
A multilaboratory study was conducted to compare performance of the GeneQuence® DNA hybridization (DNAH) method incorporating new 24 h enrichment protocols and reference culture procedures for detection of Salmonella spp. in select foods. Six food types (raw ground turkey, raw ground beef, dried whole egg, milk chocolate, walnuts, and dry pet food) were tested by the DNAH method and by the culture methods of either the U.S. Department of Agriculture-Food Safety and Inspection Service (USDA-FSIS) or the U.S. Food and Drug Administration's Bacteriological Analytical Manual (FDA/BAM). Fifteen laboratories participated in the study. Four of the foods tested (raw ground turkey, dried whole egg, milk chocolate, and dry pet food), showed no statistically significant differences in performance between the DNAH method and the reference procedure as determined by Chi square analysis. Sensitivity rates for the DNAH method ranged from 92 to 100. The DNAH method, with the specific enrichment protocol evaluated, was found to be ineffective for detection of Salmonella spp. in walnuts. For raw ground beef, results from one trial showed a statistically significant difference in performance, with more positives obtained by the reference method. However, evidence suggests that the difference in the number of positives was likely due to lack of homogeneity of the test samples rather than to DNAH method performance.
Collapse
Affiliation(s)
| | - Xuan Peng
- Neogen Corp., 620 Lesher Pl, Lansing, MI 48912
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Gutierrez M, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Lam W, Chiu J, Lee J, Yang J, Garon E, Basso A, Ma H, Fong L, Snyder A, Yuan J, Herbst R. P1.01-107 KEYNOTE-495/KeyImPaCT: Phase 2 Biomarker-Directed Study of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.822] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
41
|
Mendieta Badimon LG, Ben-Aicha S, Casani L, Gutierrez M, Carreras F, Sabate M, Badimon L, Vilahur G. 2183Intravenous administration of IV-STATIN CARDIOSHIELD during myocardial infarction renders higher cardioprotection than oral atorvastatin given shortly after reperfusion: a translational CMR study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Statins are known to exert rapid cardioprotective effects irrespective of their lipid-lowering properties. Several trials have suggested that high-dose statin treatment may reduce cardiovascular complications in patients undergoing invasive management. However, the ideal timing and administration regime is not clear.
Purpose
We compared the cardioprotective effects derived from IV-STATIN CARDIOSHIELD® administered intravenously during myocardial infarction (MI) with those attained by oral atorvastatin administration shortly after reperfusion. This study was conducted in a preclinical pig model of MI by serial CMR imaging.
Methods
Diet-induced hypercholesterolemic pigs (N=21; cholesterol: 387±74mg/dL) were subjected to 90 minutes of complete coronary occlusion (closed-chest model of MI), then reperfusion was established and animals were kept for 42 days. Within this experimental design animals were distributed in 3 groups (G) (7animals/arm): G1) animals received an intravenous bolus (0.3mg/kg) of IV-STATIN during MI; G2) animals received an intravenous bolus of the vehicle during MI (placebo-control); and G3) animals were administered atorvastatin p.o. initiated within the first 2h post-MI (Atorva-post-MI). G1 and G3 animals remained on atorvastatin p.o. for the following 42 days whereas G2 controls received placebo-pills. We assessed cardiac damage and global and regional functional parameters by CMR at day3 and day42 post-MI. Myocardial samples were processed for molecular studies on cardiac remodeling-related parameters (collagen and AMPK).
Results
CMR analysis at day-3 revealed that G1 pigs showed a marked reduction in infarct size as compared to both G3 and G2 animals (19.1±2.8% LV vs. 29.0±1.8% and 29.3%±3.2%, respectively; p<0.05) with a resultant 50% increase in myocardial salvage (p<0.05 vs. both). At day-42 both G1 and G3 animals showed a significant decrease in the size of the scar vs. G2 animals; however, G1 animals showed a further 24% scar reduction as compared to G3 (14.4±1.1% vs. 18.8±1.0% LV; p<0.05). Functional analyses revealed higher LVESV in G1 animals as compared to G2 (p<0.05) and less wall motion abnormalities in the jeopardized myocardium (p<0.05) vs. both groups at day42 post-MI. Collagen expression and AMPK activation were found to be significantly enhanced in the scar of G1 (p<0.05 vs. both groups). No changes were detected in lipids levels or liver and renal parameters throughout the study in any pig group.
Conclusions
Intravenous IV-STATIN CARDIOSHIELD® treatment during MI limited cardiac damage and improved cardiac function and remodeling to a larger extent than when atorvastatin was administered orally shortly after reperfusion. Our results support this novel regime of intravenous administration of IV-STATIN CARDIOSHIELD® as a routine procedure during MI. Further investigation of the potential benefits of this new therapeutic approach in STEMI patients is warranted.
Collapse
Affiliation(s)
| | - S Ben-Aicha
- Cardiovascular Research Program -ICCC, IR-Hospital de Sant Pau, Barcelona, Spain
| | - L Casani
- Cardiovascular Research Program -ICCC, IR-Hospital de Sant Pau, Barcelona, Spain
| | - M Gutierrez
- Cardiovascular Research Program -ICCC, IR-Hospital de Sant Pau, Barcelona, Spain
| | - F Carreras
- Hospital de la Santa Creu i Sant Pau, Cardiology, Barcelona, Spain
| | - M Sabate
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - L Badimon
- Cardiovascular Research Program -ICCC, IR-Hospital de Sant Pau, Barcelona, Spain
| | - G Vilahur
- Cardiovascular Research Program -ICCC, IR-Hospital de Sant Pau, Barcelona, Spain
| |
Collapse
|
42
|
Vilahur G, Ben-Aicha S, Gutierrez M, Arzanauskaite M, Mendieta Badimon LG, Arderiu G, Casani L, Badimon L. P3490Intravenous administration of atorvastatin early after cardiac ischemia attenuates adverse left ventricular remodeling, ameliorates cardiac function and limits the deleterious effects of reinfarction. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Statins have shown to attenuate reperfusion-induced myocardial injury. However, whether statins directly target ischemia-related cardiac damage attenuating adverse left ventricular (LV) remodeling and post-myocardial infarction (MI) complications remains unknown.
Purpose
We examined the impact of a single intravenous administration of IV-STATIN early after ischemia onset on LV remodeling and reinfarction in a dyslipidemic pig model by serial CMR.
Methods
Diet-induced hypercholesterolemic pigs (N=14; cholesterol: 394±61mg/dL) were subjected to 90min of ischemia (MI-induction by LAD-coronary balloon occlusion) and further reperfusion. One group of pigs received an intravenous bolus of IV-STATIN (a modified preparation of atorvastatin; 0.3mg/kg) at 15min of ischemia (IV-STATIN-ISCH; n=7) whereas the other was orally treated with atorvastatin shortly post-MI (ATORVA-POST-MI; n=7). 40 days thereafter animals underwent a second MI-induction (reinfarction) and were sacrificed at day43. All animals remained post-MI and until sacrifice on p.o. atorvastatin treatment and a high-cholesterol diet. Serial CMR analysis was performed at day3 (early LV remodeling), prior-reinfarction (late LV remodeling; day40) and post-reinfarction (day43) for the assessment of global anatomical and functional parameters and segmental motility. Myocardial tissue was collected for molecular and histological analyses of cell death-, inflammatory-, and angiogenic-related markers.
Results
CMR revealed 3 days post-MI an absolute 6% reduction on infarct size in IV-STATIN-ISCH pigs as compared to ATORVA-POST-MI pigs (18.0±0.8% LV vs. 23.9±1.9% LV; p<0.05) with the resultant 25% increase in myocardial salvage (p<0.05). These infarct size-limiting effects remained up to day40 and lead to 30% smaller scars vs. ATORVA-POST-MI pigs (9.9±0.8% LV vs. 13.9±1.9% LV; respectively; p=0.06). Interestingly, reinfarction did not expand the damage produced by MI in IV-STATIN-ISCH animals whereas it increased by 13% the scar size of ATORVA-POST-MI pigs (p<0.05). These IV-STATIN-ISCH- related benefits detected throughout the study were associated with a significant global improvement in stroke volume and LVEF as well and less regional wall motion abnormalities and dysfunctional segments in the jeopardized region (p<0.05 vs. ATORVA-POST-MI). The scar of reinfarcted IV-STATIN-ISCH pigs showed lower apoptosis execution and MCP-1 expression and higher vessel density vs. ATORVA-POST-MI (p<0.05). Lipids levels and liver/renal parameters remained unchanged in all animals throughout the study.
Conclusions
This is the first study to prove that intravenous administration of IV-STATIN early after MI improves structural and functional cardiac remodeling and limits the worsening effects of reinfarction. The potential cardiac benefits afforded by CardioshieldTM infusion early after MI-diagnosis (i.e., out-of-hospital and/or cath lab setting) deserves to be clinically investigated.
Acknowledgement/Funding
Fundaciό Investigaciό Marato TV3 #20154310; PNS 2015-71653-R and PNS SAF2016-76819-R MINECO, ISCIII; CIBERCV CN16/11/00411
Collapse
Affiliation(s)
- G Vilahur
- Cardiovascular Research Program - ICCCC, IR Hospital de Sant Pau, Barcelona, Spain
| | - S Ben-Aicha
- Cardiovascular Research Program - ICCCC, IR Hospital de Sant Pau, Barcelona, Spain
| | - M Gutierrez
- Cardiovascular Research Program - ICCCC, IR Hospital de Sant Pau, Barcelona, Spain
| | - M Arzanauskaite
- Cardiovascular Research Program - ICCCC, IR Hospital de Sant Pau, Barcelona, Spain
| | | | - G Arderiu
- Cardiovascular Research Program - ICCCC, IR Hospital de Sant Pau, Barcelona, Spain
| | - L Casani
- Cardiovascular Research Program - ICCCC, IR Hospital de Sant Pau, Barcelona, Spain
| | - L Badimon
- Cardiovascular Research Program - ICCCC, IR Hospital de Sant Pau, Barcelona, Spain
| |
Collapse
|
43
|
Bryant-Stephens T, Kenyon C, Apter AJ, Wolk C, Williams YS, Localio R, Toussaint K, Hui A, West C, Stewart Y, McGinnis S, Gutierrez M, Beidas R. Creating a community-based comprehensive intervention to improve asthma control in a low-income, low-resourced community. J Asthma 2019; 57:820-828. [PMID: 31082287 DOI: 10.1080/02770903.2019.1619083] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Introduction: Asthma evidence-based interventions (EBI) are implemented in the home, school, community or primary care setting. Although families are engaged in one setting, they often have to navigate challenges in another setting.Objective: Our objective is to design and implement a comprehensive plan which integrates EBI's and connects the four sectors in underserved communities such as Philadelphia.Methods: September 2015-April 2016 we implemented a three-pronged strategy to understand needs and resources of the community including 1) focus groups and key informant interviews, 2) secondary data analysis and 3) pilot testing for implementation to determine gaps in care, and opportunities to overcome those gaps.Results: Analysis of the focus group and key informant responses showed themes: diagnosis fear, clinician time, home and school asthma trigger exposures, school personnel training and communication gaps across all four sectors. EBI's were evaluated and selected to address identified themes. Pilot testing of a community health worker (CHW) intervention to connect home, primary care and school resulted in an efficient transfer of asthma medications and medication administration forms to the school nurse office for students with uncontrolled asthma addressing a common delay leading to poor asthma management in school.Conclusion: Thus far there has been limited success in reducing asthma disparities for low-income minority children. This study offers hope that strategically positioning CHWs may work synergistically to close gaps in care and result in improved asthma control and reduced asthma disparities.
Collapse
Affiliation(s)
- Tyra Bryant-Stephens
- The Children's Hospital of Philadelphia Community Asthma Prevention Program, Philadelphia, PA, USA.,University of Pennsylvania/Perelman School of Medicine, Philadelphia, PA, USA
| | - C Kenyon
- The Children's Hospital of Philadelphia Community Asthma Prevention Program, Philadelphia, PA, USA.,University of Pennsylvania/Perelman School of Medicine, Philadelphia, PA, USA
| | - A J Apter
- University of Pennsylvania/Perelman School of Medicine, Philadelphia, PA, USA
| | - Courtney Wolk
- University of Pennsylvania/Perelman School of Medicine, Philadelphia, PA, USA.,Department of Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA
| | - Yolanda S Williams
- The Children's Hospital of Philadelphia Community Asthma Prevention Program, Philadelphia, PA, USA
| | - R Localio
- University of Pennsylvania/Perelman School of Medicine, Philadelphia, PA, USA
| | - K Toussaint
- The Children's Hospital of Philadelphia Community Asthma Prevention Program, Philadelphia, PA, USA
| | - A Hui
- Philadelphia Health Management Corporation, Philadelphia, PA, USA
| | - C West
- Philadelphia Health Management Corporation, Philadelphia, PA, USA
| | | | - S McGinnis
- Philadelphia Health Management Corporation, Philadelphia, PA, USA
| | - M Gutierrez
- Philadelphia Health Management Corporation, Philadelphia, PA, USA
| | - R Beidas
- Department of Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.,Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.,Penn Implementation Science Center at the Leonard Davis Institute of Health Economics (PISCE@LDI), University of Pennsylvania, PA, USA
| |
Collapse
|
44
|
Mato A, Barrientos J, Brander D, Pagel J, Gutierrez M, Kadish K, Tomlinson B, Ghosh N, Giafis N, Ipe D, Upasani S, Sundaram M, Ferrante L, Amaya-Chanaga C, Iyengar R, Sharman J. PF383 PROGNOSTIC TESTING AND TREATMENT APPROACHES BASED ON REAL-WORLD CLINICAL EXPERIENCE FROM AN INTERIM ANALYSIS OF THE INFORMCLL REGISTRY OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000559744.42031.cf] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
45
|
Small Layne A, Pedroso J, Gutierrez M. 31: Laparoscopic ultrasound during myomectomy. Am J Obstet Gynecol 2019. [DOI: 10.1016/j.ajog.2019.01.167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
46
|
Yardley DA, Abu-Khalaf M, Boni V, Brufsky A, Emens LA, Gutierrez M, Hurvitz S, Im SA, Loi S, McCune SL, Schmid P, O'Hear C, Zhang X, Vidal GA. Abstract OT2-06-04: MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with hormone receptor–positive and triple-negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot2-06-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Cancer immunotherapy (CIT) has significantly improved overall survival across multiple tumor types, but only subsets of patients experience durable response with single-agent CIT. Combinations of CIT with targeted therapy or chemotherapy may be needed in order to target multiple cancer immune escape mechanisms simultaneously, thus providing personalized treatment options that extend clinical benefit to more patients. The MORPHEUS platform includes multiple phase Ib/II trials designed to identify early signals of safety and activity of CIT combinations. Using a randomized trial design, multiple CIT combination arms are compared with a single standard-of-care control arm. These trials have the flexibility to open new treatment arms with novel CIT combinations as they become available and to close arms that show minimal activity or unacceptable toxicity. Here we describe MORPHEUS trials in patients with metastatic or unresectable locally advanced hormone receptor–positive (HR+BC) or triple-negative breast cancer (TNBC), 2 patient populations in need of more treatment options.
Trial design:
MORPHEUS-HR+BC (NCT03280563) will enroll patients with metastatic or unresectable locally advanced HR+BC who have progressed during or after first-line treatment with a cyclin-dependent kinase (CDK) 4/6 inhibitor and whose tumors do not express human epidermal growth factor 2 (HER2). MORPHEUS-TNBC (NCT03424005) will enroll patients with metastatic or unresectable locally advanced TNBC who have progressed during or after first-line treatment with chemotherapy. For both studies, key inclusion criteria include Eastern Cooperative Oncology Group performance status of 0-1 (stage 1) or 0-2 (stage 2) and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Key exclusion criteria include prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies, and symptomatic, untreated, or actively progressing central nervous system metastases. Patients in both trials will be randomized to one of the CIT atezolizumab combination arms or a control arm (up to 5 arms in HR+BC and up to 6 arms in TNBC). Patients experiencing loss of clinical benefit or unacceptable toxicity in stage 1 may be eligible to switch to a different CIT atezolizumab combination arm in stage 2. Primary endpoints are safety measures and investigator-assessed objective response rate per RECIST v1.1. Progression-free survival, overall survival, duration of response, clinical benefit rate (HR+BC) or disease control rate (TNBC) are among the secondary endpoints. Exploratory biomarkers will also be examined.
Citation Format: Yardley DA, Abu-Khalaf M, Boni V, Brufsky A, Emens LA, Gutierrez M, Hurvitz S, Im S-A, Loi S, McCune SL, Schmid P, O'Hear C, Zhang X, Vidal GA. MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with hormone receptor–positive and triple-negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-06-04.
Collapse
Affiliation(s)
- DA Yardley
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| | - M Abu-Khalaf
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| | - V Boni
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| | - A Brufsky
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| | - LA Emens
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| | - M Gutierrez
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| | - S Hurvitz
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| | - S-A Im
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| | - S Loi
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| | - SL McCune
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| | - P Schmid
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| | - C O'Hear
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| | - X Zhang
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| | - GA Vidal
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Thomas Jefferson University Hospital, Philadelphia, PA; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain; Medical Oncology, Magee-Women's Hospital of UPMC, Pittsburgh, PA; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Hackensack University Medical Center John Theurer Cancer Center, Hackensack, NJ; Geffen School of Medicine at UCLA, Los Angeles, CA; Seoul National University Hospital, Seoul, Korea; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Northwest Georgia Oncology Centers, Marietta, GA; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Genentech, Inc., South San Francisco, CA; University of Tennessee West Cancer Center, Germantown, TN
| |
Collapse
|
47
|
Aydinyan S, Kirakosyan H, Zakaryan M, Abovyan L, Kharatyan S, Peikrishvili A, Mamniashvili G, Godibadze B, Chagelishvili E, Lesuer D, Gutierrez M. Fabrication of Cu-W Nanocomposites by Integration of Self-Propagating High-Temperature Synthesis and Hot Explosive Consolidation Technologies. Eurasian Chem Tech J 2018. [DOI: 10.18321/ectj763] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Manufacturing W-Cu composite nanopowders was performed via joint reduction of CuO and WO3 oxides with various ratios (W:Cu = 2:1, 1:1, 1:3, 1:13.5) using combined Mg–C reducer. Combustion synthesis was used to synthesize homogeneous composite powders of W-Cu and hot explosive consolidation (HEC) technique was utilized to fabricate dense compacts from ultrafine structured W-Cu powders. Compact samples obtained from nanometer sized SHS powders demonstrated weak relation between the susceptibility and the applied magnetic field in comparison with the W and Cu containing micrometer grain size of metals. The density, microstructural uniformity and mechanical properties of SHS&HEC prepared samples were also evaluated. Internal friction (Q-1) and Young modulus (E) of fabricated composites studied for all samples indicated that the temperature 1000 °С is optimal for full annealing of microscopic defects of structure and internal stresses. Improved characteristics for Young modulus and internal friction were obtained for the W:Cu = 1:13.5 composite. According to microhardness measurement results, W-Cu nanopowders obtained by SHS method and compacted by HEC technology were characterized by enhanced (up to 85%) microhardness.
Collapse
|
48
|
Sisto J, Garg N, Gutierrez M, Stockwell E. Ureteral Anatomy for the Junior Learner. J Minim Invasive Gynecol 2018. [DOI: 10.1016/j.jmig.2018.09.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Gutierrez M, Wozniak A, Langer C, Fang B, Suero-Abreu G, Norden A, Bedell K, Schaffer J, Collins A, Schultz E, Stone B, Narayanan V, Goldberg S. P2.01-42 Impact of Tobacco Smoking on Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer in the Era of Targeted Therapy. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1096] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
50
|
Cho B, Perets R, Bar J, Ahn MJ, Kim DW, Yoh K, Nagrial A, Spigel D, Lee D, Gutierrez M, Kotasek D, Siddiqi S, Chain A, Butts B, Zhang Y, Li X, Cyrus J, Tse A, Altura R, Rasco D. Phase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy279.402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|